Di Zhe Pharmaceutical Co., Ltd. (688192.SH) is expected to incur a net loss of approximately 865 million yuan in 2024, with a year-on-year increase in revenue of around 294.35%.

Di Zhe Pharmaceutical (688192.SH) announced that, according to preliminary estimates by the finance department, it is expected to achieve an operating income of approximately 360 million yuan in 2024, an increase of around 268.7114 million yuan compared to the same period last year, representing a year-on-year increase of about 294.35%. The research and development expenses for the year 2024 are expected to be around 738 million yuan, a decrease of approximately 67.5985 million yuan compared to the same period last year, representing a year-on-year decrease of about 8.39%. It is expected that the net loss attributable to the owners of the parent company for the year 2024 will be around 865 million yuan, a decrease of approximately 242.7133 million yuan compared to the same period last year, representing a year-on-year decrease of about 21.91%. The net loss after deducting non-recurring gains and losses attributable to the owners of the parent company for the year 2024 is expected to be around 918 million yuan, a decrease of approximately 242.7271 million yuan compared to the same period last year, representing a year-on-year decrease of about 20.91%. The company is expected to see a significant increase in operating income in 2024, and progress in product research and development is proceeding smoothly with high levels of investment. Therefore, it is anticipated that the net profit attributable to the owners of the parent company will continue to be negative. However, there have been no significant adverse changes in the company's main business and core competitiveness.